Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    KO-ERK-001
Previous Study | Return to List | Next Study

First-in-Human Study of KO-947 in Non-Hematological Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03051035
Recruitment Status : Active, not recruiting
First Posted : February 13, 2017
Last Update Posted : June 23, 2020
Sponsor:
Information provided by (Responsible Party):
Kura Oncology, Inc.

Brief Summary:
This phase 1 first-in-human (FIH) dose escalation study will determine the maximum tolerated dose (MTD) of KO-947 in subjects with locally advanced unresectable or metastatic, relapsed and/or refractory, non-hematological malignancies. If an MTD cannot be identified, a recommended phase 2 dose (RP2D) will be determined. In addition, two tumor specific extension cohorts may be conducted to further characterize the safety and tolerability of KO-947 and provide preliminary evidence of anti-tumor activity.

Condition or disease Intervention/treatment Phase
Advanced Malignant Neoplasm Drug: KO-947 Phase 1

Detailed Description:

This phase 1 first-in-human (FIH) dose escalation study will determine the maximum tolerated dose (MTD) of KO-947 in subjects with locally advanced unresectable or metastatic, relapsed and/or refractory, non-hematological malignancies. If an MTD cannot be identified, a recommended phase 2 dose (RP2D) will be determined. In addition, two tumor specific extension cohorts may be conducted to further characterize the safety and tolerability of KO-947 and provide preliminary evidence of anti-tumor activity. Three dosing schedules will be executed (Schedule 1, 2, or 3).

Screening evaluations will be completed following signing of informed consent and within either 21 days or 28 days of Cycle 1 Day 1. Evaluations performed as part of the standard of care within 21/28 days of dosing but prior to consent do not need to be repeated. By signing the consent form, study subjects agree to the collection of standard of care health information.

The study will consist of three parts: dose escalation, MTD expansion and tumor specific extension.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 First-in-Human Study of KO-947 in Locally Advanced Unresectable or Metastatic, Relapsed and/or Refractory Non-Hematological Malignancies
Actual Study Start Date : April 6, 2017
Estimated Primary Completion Date : December 31, 2020
Estimated Study Completion Date : December 31, 2020

Arm Intervention/treatment
Experimental: KO-947 Drug: KO-947
Intravenous administration




Primary Outcome Measures :
  1. To determine the maximal tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of KO-947 in subjects with locally advanced unresectable or metastatic, relapsed and/or refractory, non-hematological malignancies. [ Time Frame: Dose-limiting toxicities will be evaluated during the first 28 days of KO-947 monotherapy treatment in the dose escalation portion of the study. ]

Secondary Outcome Measures :
  1. Number of patients that experience Adverse Events (AEs) [ Time Frame: Until 30 days after the end of study ]
    Adverse Events (AEs) and Serious Adverse Events (SAEs) will be graded according to the NCI-CTCAE (Version 4.03)

  2. Maximum plasma concentration (Cmax) of KO-947 on Cycle 1 Day 1 and Cycle 2 Day 1 [ Time Frame: Blood samples for determination of KO-947 concentration will be collected at 0, 1, end of infusion, 1.5 2, 2.5 3, 3.5, 4, 6, 8, 24 hours during dose escalation and dose expansion. ]
  3. Plasma concentration of KO-947 over 24 hours after dosing on Cycle 1 Day 1 and Cycle 2 Day 1 [ Time Frame: Blood samples for determination of KO-947 concentration will be collected at 0, 1, end of infusion, 1.5 2, 2.5 3, 3.5, 4, 6, 8, 24 hours during dose escalation and dose expansion. ]
  4. Time to maximum plasma concentration (tmax) of KO-947 on Cycle 1 Day 1 and Cycle 2 Day 1 [ Time Frame: Blood samples for determination of KO-947 concentration will be collected at 0, 1, end of infusion, 1.5 2, 2.5 3, 3.5, 4, 6, 8, 24 hours during dose escalation and dose expansion. ]
  5. Time to the last detectable plasma concentration (tlast) of KO-947 on Cycle 1 Day 1 and Cycle 2 Day 1 [ Time Frame: Blood samples for determination of KO-947 concentration will be collected at 0, 1, end of infusion, 1.5 2, 2.5 3, 3.5, 4, 6, 8, 24 hours during dose escalation and dose expansion. ]
  6. Terminal half-life (t½λz) of KO-947 on Cycle 1 Day 1 and Cycle 2 Day 1 [ Time Frame: Blood samples for determination of KO-947 concentration will be collected at 0, 1, end of infusion, 1.5 2, 2.5 3, 3.5, 4, 6, 8, 24 hours during dose escalation and dose expansion. ]
  7. Area under the plasma concentration-time curve for KO-947 from zero to 24 hours [AUC(0-24)] on Cycle 1 Day 1 and Cycle 2 Day 1 [ Time Frame: Blood samples for determination of KO-947 concentration will be collected at 0, 1, end of infusion, 1.5 2, 2.5 3, 3.5, 4, 6, 8, 24 hours during dose escalation and dose expansion. ]
  8. Area under the plasma concentration-time curve for KO-947 from zero to the last detectable plasma concentration [AUC(0-last)] on Cycle 1 Day 1 and Cycle 2 Day 1 [ Time Frame: Blood samples for determination of KO-947 concentration will be collected at 0, 1, end of infusion, 1.5 2, 2.5 3, 3.5, 4, 6, 8, 24 hours during dose escalation and dose expansion. ]
  9. Trough plasma concentration (Ctrough) of KO-947 on Cycle 1 Day 1 and Cycle 2 Day 1 [ Time Frame: Blood samples for determination of KO-947 concentration will be collected at 0, 1, end of infusion, 1.5 2, 2.5 3, 3.5, 4, 6, 8, 24 hours during dose escalation and dose expansion. ]
  10. Objective Response Rate (ORR), Progression Free Survival (PFS) and Duration of Response (DOR) of KO-947 [ Time Frame: 36 months (approximately 24 months accrual + 12 months follow-up) ]
    Tumor assessments will be performed approximately every 12 weeks (Schedules 1 and 2) or every 9 weeks (Schedule 3) until disease progression.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  1. Subject has a locally advanced unresectable or metastatic, relapsed and/or refractory, non-hematological malignancy for which treatment with an approved agent that is considered standard of care in the indication either does not exist or has proven ineffective.
  2. To be enrolled in the dose escalation or in the MTD expansion, Subject must have a locally confirmed diagnosis of either of the following tumor types:

    1. Malignancy of non-squamous histology that carries a BRAF, KRAS, NRAS or HRAS mutation(s).
    2. Malignancy of squamous histology. In cases of mixed histology, squamous must be the predominant histology.
  3. Upon the identification of an MTD or RP2D, the Sponsor, in consultation with the study investigators, may open the enrollment of two of the following nonrandomized tumor specific extension cohorts: Subject must have a locally confirmed diagnosis of either of the following tumor types:

    1. RASMUT/BRAFMUT NSCLC: Subject must have a locally confirmed diagnosis of RAS (NRAS, KRAS, HRAS) or BRAF mutated non-small cell malignancies of the lung. Subject must have received at least 1 prior approved regimen for locally advanced or metastatic disease followed by documented progressive disease.
    2. SCCHN and/or SCCE: Subject must have a locally confirmed diagnosis of SCCHN or SCCE with amplification of the 11q13 chromosome. Subject must have received at least 1 prior approved agent for advanced or metastatic disease followed by documented progressive disease. For subjects with 11q13 amplification, the tumor must have >3 copies of the 11q13 chromosome as determined by a methodology approved by the Sponsor.
  4. Subject has at least one measurable lesion per RECIST v1.1.
  5. For the MTD/RP2D expansion cohort, Subject must have an accessible tumor lesion(s) and consent to tumor biopsy of such a lesion(s) during screening and after starting KO-947 treatment for the analysis of ERK pathway signalling and biological effects.
  6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  7. Serum albumin ≥ 2.8 g/dL
  8. Acceptable liver function:

    1. Bilirubin ≤ 1.5 times upper limit of normal (x ULN); if liver metastases are present, then ≤ 2 x ULN is allowed. Criteria does not apply to subjects with Gilbert's syndrome diagnosed as per institutional guidelines.
    2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x ULN; if liver metastases are present, then ≤ 5 x ULN is allowed.
  9. Acceptable renal function with serum creatinine ≤ 1.5 x ULN or a calculated creatinine clearance ≥ 50 mL/min using the Cockcroft-Gault or Modification of Diet in Renal Disease formulas.
  10. Acceptable hematologic status:

    1. Absolute neutrophil count (ANC) ≥ 1500 cells/μL
    2. Platelet count ≥ 100,000/μL
    3. Hemoglobin ≥ 9.0 g/dL

Exclusion Criteria:

  1. Ongoing treatment with an anticancer agent.
  2. History of prior significant toxicity (Grade 2 or higher that required permanent treatment discontinuation) from a BRAF, MEK (MAPK [Mitogen-activated protein]/ERK kinase) or ERK inhibitor.
  3. History of retinal vein occlusion, neurosensory retinal detachment, or neovascular macular degeneration. Evidence of visible retinal pathology as assessed by ophthalmologic examination that is considered a risk factor for retinal vein thrombosis or neurosensory retinal detachment.
  4. Mean QTcF of >470 ms on triplicate ECGs performed within 5 minutes of each other; subjects currently taking drugs known to be associated with prolonging the QT interval for which there are no adequate therapeutic substitutes; subjects with congenital long QT syndrome. As a guide to known drugs associated with QTc prolongation, please refer to the following Credible Meds web page for a list of drugs that prolong QT and/or cause torsades de pointes, https://crediblemeds.org/pdftemp/pdf/CombinedList.pdf
  5. Allergy or hypersensitivity to components of the KO-947 formulation, e.g. dextrose, hydroxypropyl beta cyclodextrin, acetic acid, sodium acetate and water for injection.
  6. Participation in any interventional study within 4 weeks of Cycle 1 Day 1 or 5 half-lives of the investigational agent(s) used in the interventional study prior to Cycle 1 Day 1 (whichever is shorter).
  7. Grade >1 gastrointestinal toxicity that cannot be managed with supportive care measures.
  8. Received treatment for unstable angina within the prior year, myocardial infarction within the prior year, cerebro-vascular attack within the prior year, history of New York Heart Association grade III or greater congestive heart failure, or current serious cardiac arrhythmia requiring medication except atrial fibrillation.
  9. Known uncontrolled brain, leptomeningeal or epidural metastases (unless treated and well controlled for at least 4 weeks prior to Cycle 1 Day 1). Controlled brain metastases that require continuous high dose corticosteroid use within 4 weeks of Cycle 1 Day 1.
  10. Major surgery, other than diagnostic surgery, within 4 weeks prior to Cycle 1 Day 1, without complete recovery.
  11. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy. Known infection with human immunodeficiency virus, or an active infection with hepatitis B or hepatitis C.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03051035


Locations
Layout table for location information
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55902
United States, New York
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
United States, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States, 19111-2497
Spain
Vall D'Hebron Institute of Oncology
Barcelona, Spain, 08035
START Madrid-HM CIOCC
Madrid, Spain, 28050
Sponsors and Collaborators
Kura Oncology, Inc.
Layout table for additonal information
Responsible Party: Kura Oncology, Inc.
ClinicalTrials.gov Identifier: NCT03051035    
Other Study ID Numbers: KO-ERK-001
First Posted: February 13, 2017    Key Record Dates
Last Update Posted: June 23, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Kura Oncology, Inc.:
non-hematological malignancies
non-squamous
squamous
BRAF
KRAS
NRAS
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms